ROBERT NELSEN
CIK 1219042 · last filed 2026-06-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$484.06M
Companies
18
Total Filings
132
Lifetime Open-Market Net
$85.61M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PRME | Director | 6,128,297 | $3.02 | $18.48M | $43.60M | 8 | 2026-06-08 |
| SANA | Director | 12,447,375 | $3.21 | $39.96M | $10.00M | 15 | 2026-06-05 |
| LYEL | Director | 910,318 | $13.19 | $12.01M | $0 | 5 | 2024-06-17 |
| VIR | Director | 7,874,803 | $8.87 | $69.81M | $20.00M | 22 | 2024-06-03 |
| BOLD | 10%+ Owner | 1,048,433 | $2.53 | $2.65M | $12.80M | 1 | 2024-04-04 |
| NMRA | 10%+ Owner | 3,758,883 | $1.64 | $6.16M | $4.20M | 1 | 2023-09-27 |
| DNLI | Director | 9,681,181 | $24.18 | $234.09M | $0 | 8 | 2021-06-04 |
| Karuna Therapeutics, Inc. (KRTX) Delisted | Director | 1,461,704 | $329.83 | $482.11M | $3.20M | 6 | 2021-04-15 |
| BEAM | Director | 3,535,572 | $25.71 | $90.90M | $0 | 3 | 2021-04-02 |
| Unity Biotechnology, Inc. (UBX) Delisted | Director | 168,242 | $0.20 | $33.7K | $0 | 4 | 2020-06-22 |
| Sienna Biopharmaceuticals, Inc. (SNNA) Delisted | Director | 2,538,641 | — | — | $0 | 3 | 2018-06-05 |
| Juno Therapeutics, Inc. (JUNO) Delisted | Director | 3,234 | — | — | $0 | 13 | 2018-03-07 |
| Syros Pharmaceuticals, Inc. (SYRS) Delisted | Director | 463,714 | $0.00 | $185 | $5.00M | 4 | 2017-09-22 |
| AGIO | Director | 118,404 | $32.80 | $3.88M | -$20.75M | 10 | 2017-03-07 |
| Sage Therapeutics, Inc. (SAGE) Delisted | Director | 1,232,649 | $8.68 | $10.70M | $0 | 6 | 2015-11-12 |
| KYTHERA BIOPHARMACEUTICALS INC (KYTH) Delisted | Director | 957,604 | — | — | $0 | 8 | 2015-03-26 |
| Bellerophon Therapeutics, Inc. (BLPH) Delisted | Director | 50,200 | $0.01 | $602 | $2.55M | 1 | 2015-02-23 |
| FATE | Director | 2,473,188 | $2.48 | $6.12M | $5.00M | 1 | 2013-10-07 |
Recent Filings · Page 2 of 14
132 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-03 | VIR | Grant (A) | +8,000 | $0 | EDGAR |
| 2024-04-04 | BOLD | Mixed | +10,502,884 | $12.80M | EDGAR |
| 2024-02-20 | PRME | Buy (P) | +3,200,000 | $20.00M | EDGAR |
| 2024-02-12 | SANA | Buy (P) | +1,818,181 | $10.00M | EDGAR |
| 2023-09-27 | NMRA | Buy (P) | +351,024 | $4.20M | EDGAR |
| 2023-09-08 | LYEL | Grant (A) | — | $0 | EDGAR |
| 2023-06-20 | LYEL | Grant (A) | — | $0 | EDGAR |
| 2023-06-16 | PRME | Grant (A) | — | $0 | EDGAR |
| 2023-06-12 | SANA | Grant (A) | — | $0 | EDGAR |
| 2023-05-24 | VIR | Grant (A) | +6,027 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.